Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KCNQ4 | P56696 | 2/20 | 0.35 |
| ▸ | KCNQ5 | Q9NR82 | 2/20 | 0.35 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 2/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27399415 | 0.79 | ALDH1A1 (0.37) | LMNAKCNQ4KCNQ5ALDH1A1GAA | |
| SCHEMBL24255781 | 0.77 | AR (0.33) | LMNAKCNQ4KCNQ5ALDH1A1GAA | |
| SCHEMBL23311454 | 0.76 | DHODH (0.39) | LMNAALDH1A1GAAL3MBTL1KDM4E | |
| SCHEMBL29260330 | 0.74 | CYP17A1 (0.35) | KCNQ4KCNQ5ALDH1A1GAAL3MBTL1 | |
| SCHEMBL23274072 | 0.73 | LCK (0.39) | AAK1LCK | |
| SCHEMBL22774665 | 0.69 | LCK (0.43) | AAK1LCK | |
| SCHEMBL22774510 | 0.68 | LCK (0.40) | LCK | |
| SCHEMBL22774869 | 0.68 | LCK (0.41) | LCK | |
| SCHEMBL23274147 | 0.66 | LCK (0.39) | KCNQ4KCNQ5AAK1LCK | |
| SCHEMBL101455 | 0.66 | RAF1 (0.42) | LMNAALDH1A1LCKKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12465653-B2 | Thienoazepine immunoconjugates, and uses thereof | BOLT BIOTHERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4048315-B1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS INC (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20230338571-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338571-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230257393-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257393-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257393-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-11654199-B2 | Thienoazepine immunoconjugates, and uses thereof | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11654199-B2 | Thienoazepine immunoconjugates, and uses thereof | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11654199-B2 | Thienoazepine immunoconjugates, and uses thereof | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| CN-115209920-A | Thienoazepine immunoconjugates and uses thereof | 博尔特生物治疗药物有限公司 | 2022-10-18 | — | — | CN | disclosed |
| EP-4048314-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | Bolt Biotherapeutics, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| EP-4048315-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | Bolt Biotherapeutics, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| WO-2021081407-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021081402-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338571-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | ICOS, CYP3A5, TPH1 | LMNA 4014/4885KCNQ4 1097/4885KCNQ5 1027/4885 |
| US-12465653-B2 | Thienoazepine immunoconjugates, and uses thereof | ICOS, CYP3A5, TPH1 | LMNA 4014/4885KCNQ4 1097/4885KCNQ5 1027/4885 |
| US-11654199-B2 | Thienoazepine immunoconjugates, and uses thereof | ICOS, CYP3A5, TPH1 | LMNA 4014/4885KCNQ4 1097/4885KCNQ5 1027/4885 |
| US-20230257393-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | HTR3D, PNMT, HTR3B | LMNA 2439/4885KCNQ4 3061/4885KCNQ5 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.